• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comorbidities and Ventricular Dysfunction Drive Excess Mid-Term Morbidity in an Indigenous Australian Coronary Revascularisation Cohort
There is a paucity of data in regards to longer term morbidity outcomes in Indigenous Australian patients undergoing coronary artery bypass grafting (CABG). No comparative data on re-infarction, stroke or reintervention rates exist. Outcome data following percutaneous coronary intervention (PCI) is also extremely limited. Addressing this gap in knowledge forms the major aim of our study.
Source: Heart, Lung and Circulation - April 24, 2018 Category: Cardiology Authors: Paul D Wiemers, Lucy Marney, Nicole White, Georgina Bough, Alistair Hustig, Wei Tan, Ching-Siang Cheng, Dong Kang, Sumit Yadav, Robert Tam, John F Fraser Tags: Original Article Source Type: research

Trends in the Use of Warfarin and Novel Oral Anticoagulants in Australia, 2013 to 2017
Background: In 2013, novel oral anticoagulants (NOACs) were added to the PBS as alternatives to warfarin for stroke prevention in atrial fibrillation (AF). Aim of this study is to examine changes in the use of oral anticoagulants (OACs) since the introduction of NOACs.
Source: Heart, Lung and Circulation - June 23, 2019 Category: Cardiology Authors: A. Dina, T. Akindele Tags: 231 Source Type: research

Revascularization Strategies in Patients With STEMI: Culprit-Only vs Multivessel Revascularization Using Percutaneous Coronary Intervention.
CONCLUSIONS: The relative frequency of multivessel vs culprit-only PCI has not changed from 2009-2015. Index complete revascularization for STEMI-MVD patients is more likely to be performed in those with worse presentations and is associated with worse in-hospital complications. PMID: 31303602 [PubMed - as supplied by publisher]
Source: The Journal of Invasive Cardiology - July 17, 2019 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Quality of Warfarin Anticoagulation in Indigenous and Non-Indigenous Australians With Atrial Fibrillation
Studies have shown that suboptimal anticoagulation quality, as measured by time in therapeutic range (TTR), affects a significant percentage of patients with atrial fibrillation (AF). However, TTR has not been previously characterised in Indigenous Australians who experience a greater burden of AF and stroke.
Source: Heart, Lung and Circulation - November 27, 2019 Category: Cardiology Authors: Mau T. Nguyen, Celine Gallagher, Bradley M. Pitman, Mehrdad Emami, Kadhim Kadhim, Jeroen M. Hendriks, Melissa E. Middeldorp, Kurt C. Roberts-Thomson, Rajiv Mahajan, Dennis H. Lau, Prashanthan Sanders, Christopher X. Wong Tags: Original Article Source Type: research

Quality of Warfarin Anticoagulation in  Indigenous and Non-Indigenous Australians With Atrial Fibrillation
Studies have shown that suboptimal anticoagulation quality, as measured by time in therapeutic range (TTR), affects a significant percentage of patients with atrial fibrillation (AF). However, TTR has not been previously characterised in Indigenous Australians who experience a greater burden of AF and stroke.
Source: Heart, Lung and Circulation - November 27, 2019 Category: Cardiology Authors: Mau T. Nguyen, Celine Gallagher, Bradley M. Pitman, Mehrdad Emami, Kadhim Kadhim, Jeroen M. Hendriks, Melissa E. Middeldorp, Kurt C. Roberts-Thomson, Rajiv Mahajan, Dennis H. Lau, Prashanthan Sanders, Christopher X. Wong Tags: Original Article Source Type: research

Anticoagulant Initiation During Hospital Admissions for Atrial Fibrillation in South-East Queensland, Australia
Anticoagulation reduces stroke risk in patients with atrial fibrillation (AF) but under-prescribing in eligible patients has been commonly reported. Introduction of the direct acting oral anticoagulants (DOACs) was considered to potentially improve prescribing due to increased anticoagulant options. At the time of release to the Australian market, there were limited studies investigating anticoagulant usage during hospitalisations for AF. Therefore, the aim of this study was to investigate prescribing of oral anticoagulants during hospitalisation admissions for AF during the time of DOAC introduction to the Australian market.
Source: Heart, Lung and Circulation - March 31, 2020 Category: Cardiology Authors: Iniya Rathinam, Shailendra Anoopkumar-Dukie, Tony Badrick, Trudy Teasdale, Nijole Bernaitis Tags: Original Article Source Type: research

692 Anticoagulation Prescription for Indigenous and Non-Indigenous Patients With Atrial Fibrillation in Central Australia
This study sought to compare anticoagulant prescribing practices in Indigenous and non-Indigenous Australians with AF in Central Australia.
Source: Heart, Lung and Circulation - November 8, 2020 Category: Cardiology Authors: N. Clarke, C. Gallagher, B. Pitman, S. Tu, N. Hanna-Rivero, N. Kangaharan, K. Roberts-Thomson, D. Lau, R. Mahajan, P. Sanders, C. Wong Source Type: research

516 Non-Vitamin K Anticoagulation for Non-Valvular Atrial Fibrillation in Regional Australia
Non-vitamin K antagonist oral anticoagulants (NOACs) are the therapy of choice for stroke prevention in patients with non-valvular atrial fibrillation and at least one risk factor. The Illawarra-Shoalhaven region local health district provides health services for around 400,000 people. In regional centres, many AF patients are managed by GPs. The purpose of this study was to identify the proportion of patients with NVAF who were prescribed different NOACs as well as determine if the dosage follows current guidelines.
Source: Heart, Lung and Circulation - November 8, 2020 Category: Cardiology Authors: J. Moragues Source Type: research

Secondary prevention therapies in acute coronary syndrome and relation to outcomes: observational study
Conclusions Use of secondary prevention therapies diminishes over time following an ACS. Patients receiving secondary prevention had decreased rates of death and MACE at 2 years.
Source: Heart Asia - January 12, 2019 Category: Cardiology Authors: Chow, C. K., Brieger, D., Ryan, M., Kangaharan, N., Hyun, K. K., Briffa, T., for the CONCORDANCE Investigators, Brieger, Xu, Kilian, Myers, Parkin, Morrison, Rajaratnam, Tattam, Waites, Baldo, Kamaladasa, Davies, Collins, Nyman, Blenkhorn, Boys, Juergens, Tags: Open access Original research Source Type: research

Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
Observational studies have demonstrated that the pneumococcal polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This may be mediated through IgM antibodies to OxLDL, which have previously been associated with cardioprotective effects. The Australian Study for the Prevention through Immunisation of Cardiovascular Events (AUSPICE) is a double-blind, randomised controlled trial (RCT) of PPV in preventing ischaemic events. Participants received PPV or placebo once at baseline and are being followed-up for incident fatal and non-fatal myocardial infarction or stroke over 6 years.
Source: Atherosclerosis - March 5, 2022 Category: Cardiology Authors: Shu Ren, Philip M. Hansbro, Wichat Srikusalanukul, Jay C. Horvat, Tegan Hunter, Alexandra C. Brown, Roseanne Peel, Jack Faulkner, Tiffany-Jane Evans, Shu Chuen Li, David Newby, Alexis Hure, Walter P. Abhayaratna, Sotirios Tsimikas, Ayelet Gonen, Joseph L. Source Type: research

Association of carbohydrate and saturated fat intake with cardiovascular disease and mortality in Australian women
Conclusions In middle-aged Australian women, moderate carbohydrate intake (41.0%–44.3% of TEI) was associated with the lowest risk of CVD, without an effect on total mortality. Increasing saturated fat intake was not associated with CVD or mortality and instead correlated with lower rates of diabetes, hypertension and obesity.
Source: Heart - May 25, 2022 Category: Cardiology Authors: Gribbin, S., Enticott, J., Hodge, A. M., Moran, L., Thong, E., Joham, A., Zaman, S. Tags: Cardiac risk factors and prevention Source Type: research

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
CONCLUSIONS: Globally, Lp(a) is measured in a small minority of patients with ASCVD and is highest in black, younger and female patients. More than 25% of patients had levels exceeding the established threshold for increased cardiovascular risk, approximately 50 mg/dL or 125 nmol/L.PMID:36252994 | DOI:10.1136/openhrt-2022-002060
Source: Atherosclerosis - October 17, 2022 Category: Cardiology Authors: Steven E Nissen Kathy Wolski Leslie Cho Stephen J Nicholls John Kastelein Eran Leitersdorf Ulf Landmesser Michael Blaha A Michael Lincoff Ryuichi Morishita Sotirios Tsimikas Junhao Liu Brian Manning Plamen Kozlovski Anastasia Lesogor Tom Thuren Taro Shiba Source Type: research

Emergent readmission and long-term mortality risk after incident atrial fibrillation hospitalisation
Conclusion This study highlights the large burden of unplanned all-cause and cardiovascular-specific readmissions within 2 years after being hospitalised for incident AF and their associated adverse impact on mortality. Concomitant comorbidities are independently associated with unplanned hospitalisations and mortality, which supports integrated multidisciplinary management of comorbidities, along with AF-targeted treatments, to improve long-term outcomes in patients with AF.
Source: Heart - February 14, 2023 Category: Cardiology Authors: Weber, C., Hung, J., Hickling, S., Li, I., Murray, K., Briffa, T. Tags: Cardiac risk factors and prevention Source Type: research

Pages: 1  2  3